Oncotelic Therapeutics, Inc.

OTLCReported to SECin USCIK 0000908259Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 7. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 7
Form 4 lines at Oncotelic Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Fein Seymour HowardCRO/CMOAwardnothing paid250 sharesJul 23, 2026Fein Seymour HowardCRO/CMOnothing paidAward · Jul 23Award250Jul 23, 2026
KING STEVEN W—Awardnothing paid250 sharesJul 21, 2026KING STEVEN Wnothing paidAward · Jul 21Award250Jul 21, 2026
MAIDA ANTHONY E IIIDIRECTOR AND CMO - TRANS. MED.Awardnothing paid1,500 sharesJul 14, 2026MAIDA ANTHONY E IIIDIRECTOR AND CMO - TRANS. MED.nothing paidAward · Jul 14Award1,500Jul 14, 2026
Saund SaranCBOAwardnothing paid1,500 sharesJul 14, 2026Saund SaranCBOnothing paidAward · Jul 14Award1,500Jul 14, 2026
Shah Amit B.CFOAwardnothing paid1,500 sharesJul 14, 2026Shah Amit B.CFOnothing paidAward · Jul 14Award1,500Jul 14, 2026